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Considering the worldwide dissemination of Aedes mosqui-
toes, several years ago some of us anticipated the globalization
of Chikungunya virus through invasion of the Americas, and
stated that the question was not whether it can happen, but
when it will happen [1].
Arboviruses present an ongoing challenge to medicine and
public health. Chikungunya virus was ﬁrst isolated in Africa in
the 1950s at the border of Tanzania and Mozambique.
Chikungunya fever is transmitted by Aedes mosquitoes. Clin-
ically, it resembles dengue fever and several other arboviral
diseases, but is more frequently associated with arthralgia [2].
For 50 years, the virus was conﬁned to sub-Saharan Africa and
Southeast Asia. Although it generally occurred in the form of
large and brutal epidemics affecting non-immune populations, it
was classiﬁed as a mildly pathogenic arthropod-borne virus,
and was rated as ‘emerging’ by the Institute of Medicine in
1992. The situation changed abruptly in 2005–2006, when a
strain of Chikungunya virus entered the South West Indian
Ocean Islands and adapted rapidly to mosquitoes of the
species Aedes albopictus through a mutation in the envelope
gene of the virus. The E1 A226V mutation is associated with
increased replication capacity in this worldwide-disseminated
and invasive vector. Since 2005, the epidemics in the Indian
Ocean, India and Southeast Asia have accounted for millions of
cases locally, and have resulted in thousands of imported cases
in Europe and the Americas. No autochthonous case was
recorded there, most probably because of the seasonal
asynchronicity with the southern hemisphere. The 2007 Italian
outbreak of Chikungunya fever (205 laboratory-conﬁrmed
cases) was fuelled by a unique patient returning from northern
India (north hemisphere) during the viraemic phase of the
infection. Later, Chikungunya virus autochthonous transmis-
sion was demonstrated in south-eastern France, with two
conﬁrmed cases in September 2010 [3].
The ﬁrst deﬁnitive evidence for autochthonous cases of
Chikungunya virus infection in the western hemisphere was
reported in December 2013 on the island of Saint-Martin, in
the French West Indies [4]. Four months later, at the end of
March 2014, there were >15 000 cases in nine Caribbean
islands in the French West Indies, and the ﬁrst documented
cases inland in South America occurred in French Guyana.
One month later, at the end of April 2014, there were cases in
15 islands of the Caribbean, and the count has reached 35 000.
Six fatalities have been reported so far [5].
Although prediction of epidemics of transmissible diseases is
a difﬁcult art, Chikungunya virus has the potential to spread
into new territories of America and Europe where competent
insect vectors are widely disseminated [6]. The immense
majority of human populations are immunologically na€ıve,
which is a prerequisite for rapid and extended spread.
Accordingly, we believe that several points need to be
raised and underlined for the public health community.
First, the situation is drastically different from that observed
in 2006 in the Indian Ocean Islands. Seasonal synchronicity
between Caribbean islands on the one hand and Europe and
central–northern America on the other hand creates a high-risk
situation: (i) for the introduction of Chikungunya virus into
Aedes populations of new territories; (ii) for endemization; and
(iii) for subsequent autochthonous clusters of cases of varying
magnitude, up to large outbreaks [7]. This process may be aided
by the fact that the Caribbean region is visited yearly by millions
of tourists from Europe and the Americas.
Second, as previously shown during the La Reunion Island
outbreak that affected approximately 40% of the island’s
population [2], laboratory capacity has permitted the identi-
ﬁcation and description of unprecedented clinical forms
(respiratory failure, cardiovascular decompensation, meningo-
encephalitis and other central nervous system problems,
severe acute hepatitis, severe cutaneous effects, and kidney
failure) and previously unrecognized modes of transmission
[2]. Approximately 200 severe cases who required medical
assistance for vital functions were reported, with a 35% fatality
rate [2]. Mother-to-neonate transmission was reported in 44
neonates aged <10 days [2].
Third, the question of safety in blood donation and the
required procedure for testing must be addressed as an
alternative to stopping blood collection. In particular, the
demonstration that asymptomatic infections exist demands the
implementation of a strategy for prevention relying on nucleic
acid testing that can be complemented with other methods,
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such as quarantine and post-donation self-reporting of febrile
illness [8].
Fourth, the media coverage of the Caribbean outbreak of
Chikungunya fever is limited, and is overshadowed by the
attention focused on the Middle East respiratory syndrome
coronavirus cases in the Arabian peninsula or the Ebola
outbreak in West Africa. However, it must be underlined that:
(i) the potential for the worldwide spread of Chikungunya
virus is much higher than the risk of dissemination of Middle
East respiratory syndrome coronavirus or Ebola virus; (ii) the
total number of cases to be expected from the introduction of
Chikungunya virus into the Americas, Europe or even both is
undoubtedly immeasurably higher; and (iii) attention and
funding should be directed to building up or maintaining an
efﬁcient surveillance system, organizing for international
coordination and information exchange in a timely manner,
and rapidly developing countermeasures, as advocated by the
American Committee on Arthropod-Borne Viruses [9].
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